Duspatal and Idiopathic pulmonary fibrosis - a phase IV clinical study of FDA data

Summary:

Idiopathic pulmonary fibrosis is found among people who take Duspatal, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Duspatal and have Idiopathic pulmonary fibrosis. It is created by eHealthMe based on reports of 492 people who have side effects when taking Duspatal from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 02, 2023

492 people reported to have side effects when taking Duspatal.
Among them, 7 people (1.42%) have Idiopathic pulmonary fibrosis.

What is Duspatal?

Duspatal has active ingredients of mebeverine hydrochloride. eHealthMe is studying from 518 Duspatal users for its effectiveness, alternative drugs and more.

What is Idiopathic pulmonary fibrosis?

Idiopathic pulmonary fibrosis (chronic lung disease) is found to be associated with 2,451 drugs and 2,105 conditions by eHealthMe.

Number of Duspatal and Idiopathic pulmonary fibrosis reports submitted per year:

Could Duspatal cause Idiopathic pulmonary fibrosis?

Gender of people who have Idiopathic pulmonary fibrosis when taking Duspatal *:

female: 100 %
male: 0.0 %

Age of people who have Idiopathic pulmonary fibrosis when taking Duspatal *:

Common drugs people take besides Duspatal *:

Common side effects people have besides Idiopathic pulmonary fibrosis *:

Insomnia (sleeplessness): 2 people, 28.57%
Cough: 2 people, 28.57%
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 2 people, 28.57%
Weight Increased: 1 person, 14.29%
Breathing Difficulty: 1 person, 14.29%
Fatigue (feeling of tiredness): 1 person, 14.29%
Hyperhidrosis (abnormally increased sweating): 1 person, 14.29%
Impaired Work Ability: 1 person, 14.29%
Memory Loss: 1 person, 14.29%
Rales (an abnormal respiratory sound characterized by fine crackles): 1 person, 14.29%

Common conditions people have *:

Hepatitis C: 3 people, 42.86%
Poor Quality Sleep: 1 person, 14.29%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Duspatal and have Idiopathic pulmonary fibrosis?

Check whether Idiopathic pulmonary fibrosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Idiopathic pulmonary fibrosis and when was it recovered:

Idiopathic pulmonary fibrosis in Duspatal

Expand to all the drugs that have ingredients of mebeverine hydrochloride:

Idiopathic pulmonary fibrosis and drugs with ingredients of mebeverine hydrochloride

Alternative drugs to, pros and cons of Duspatal:

Duspatal (518 reports)

Idiopathic pulmonary fibrosis treatments and more:

Idiopathic pulmonary fibrosis (68,080 reports)

COVID vaccines that are related to Idiopathic pulmonary fibrosis:

Common drugs associated with Idiopathic pulmonary fibrosis:

How the study uses the data?

The study uses data from the FDA. It is based on mebeverine hydrochloride (the active ingredients of Duspatal) and Duspatal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.